Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | VNN1 | O95497 | 3/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390094 | 0.92 | MAPK14 (0.50) | MEN1KMT2AVNN1ACACBROCK2 | |
| SCHEMBL4013506 | 0.91 | GAA (0.48) | MEN1KMT2AVNN1ACACBROCK2 | |
| SCHEMBL17730184 | 0.87 | DRD4 (0.48) | MEN1KMT2AVNN1ACACBNAMPT | |
| SCHEMBL17730185 | 0.87 | DRD4 (0.48) | MEN1KMT2AVNN1ACACBNAMPT | |
| SCHEMBL4007421 | 0.85 | EPHX2 (0.51) | ROCK2HDAC6 | |
| SCHEMBL17818371 | 0.82 | MEN1 (0.56) | MEN1KMT2AACACBHDAC6POLB | |
| SCHEMBL4399538 | 0.80 | HPGD (0.61) | MEN1KMT2AHDAC6POLB | |
| SCHEMBL2305837 | 0.77 | ALDH1A1 (0.45) | MEN1KMT2AVNN1ACACBNAMPT | |
| SCHEMBL5368326 | 0.77 | TPSAB1 (0.56) | HDAC6 | |
| SCHEMBL6203164 | 0.76 | GPR139 (0.57) | ACACBNAMPTGPR139GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | MEN1 4443/4885KMT2A 1754/4885VNN1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.